Cantor Fitzgerald Comments on Organogenesis Holdings Inc.'s FY2024 Earnings (NASDAQ:ORGO)

Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) - Stock analysts at Cantor Fitzgerald upped their FY2024 earnings per share (EPS) estimates for Organogenesis in a report released on Wednesday, October 9th. Cantor Fitzgerald analyst R. Osborn now expects that the company will post earnings of ($0.17) per share for the year, up from their prior forecast of ($0.20). The consensus estimate for Organogenesis' current full-year earnings is ($0.19) per share.

Organogenesis (NASDAQ:ORGO - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.11). Organogenesis had a negative net margin of 3.69% and a negative return on equity of 6.03%. The company had revenue of $130.23 million for the quarter, compared to the consensus estimate of $122.48 million.

Separately, Lake Street Capital initiated coverage on Organogenesis in a report on Friday, June 28th. They set a "buy" rating and a $5.00 price target for the company.

Organogenesis Trading Up 5.9 %

Shares of ORGO traded up $0.17 during trading hours on Friday, reaching $3.07. The stock had a trading volume of 206,202 shares, compared to its average volume of 853,271. The company has a market cap of $406.99 million, a P/E ratio of -23.69 and a beta of 1.60. The company has a quick ratio of 2.42, a current ratio of 2.73 and a debt-to-equity ratio of 0.22. Organogenesis has a 52 week low of $1.96 and a 52 week high of $4.70. The firm has a 50-day moving average of $2.76 and a 200 day moving average of $2.75.

Institutional Trading of Organogenesis

Several large investors have recently bought and sold shares of the business. Assenagon Asset Management S.A. grew its holdings in Organogenesis by 309.3% in the second quarter. Assenagon Asset Management S.A. now owns 3,977,124 shares of the company's stock valued at $11,136,000 after purchasing an additional 3,005,450 shares during the period. Acadian Asset Management LLC raised its position in Organogenesis by 18.6% during the first quarter. Acadian Asset Management LLC now owns 3,001,679 shares of the company's stock valued at $8,521,000 after buying an additional 471,741 shares during the period. GSA Capital Partners LLP increased its position in Organogenesis by 102.8% in the 1st quarter. GSA Capital Partners LLP now owns 531,218 shares of the company's stock worth $1,509,000 after purchasing an additional 269,315 shares during the last quarter. Los Angeles Capital Management LLC boosted its stake in shares of Organogenesis by 45.9% during the 1st quarter. Los Angeles Capital Management LLC now owns 500,567 shares of the company's stock worth $1,422,000 after acquiring an additional 157,575 shares in the last quarter. Finally, Principal Financial Group Inc. bought a new stake in shares of Organogenesis in the 1st quarter worth approximately $100,000. Hedge funds and other institutional investors own 49.57% of the company's stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.